Identification and neuroprotective properties of NA-184, a calpain-2 inhibitor.
Journal Information
Full Title: Pharmacol Res Perspect
Abbreviation: Pharmacol Res Perspect
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST STATEMENT MB, XB, YW, and YLL are cofounders of NeurAegis, Inc., a start‐up company developing calpain‐2 inhibitors for the treatment of various neurodegenerative disorders."
"This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through The Defense Medical Research and Development Program under Award No. W81XWH‐19‐1‐0329. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. Grant #BA170606. “Optimization of a selective calpain‐2 inhibitor for prolonged field care in Traumatic Brain Injury”. XB is supported in part by funds from the Daljit and Elaine Sarkaria Chair."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025